Molecular screening of patients with FGFR alterations for a phase 1 (Ph1) study with the selective FGFR inhibitor (FGFRi) Debio 1347

Presented at AACR 2019, Atlanta, GA, US

D.R. Borger¹, A. Vivancos², M. Voss³ , J. Cleary⁴, F. Meric-Bernstam⁵, J. Tabernero², K. Flaherty⁶, N. Ishii⁷, F. Brichory⁸, H. Tanaka⁸, A. Pokorska-Bocci⁸, C. Zanna⁸, J. Baselga³, A. J. Iafrate¹, P. Nuciforo²

1. Massachusetts General Hospital, Boston, MA,
2. Vall d’Hebron Institute of Oncology, Barcelona, Spain,
3. Memorial Sloan-Kettering Cancer Center, New York, NY,
4. Dana-Farber Cancer Institute, Boston, MA,
5. The University of Texas MD Anderson Cancer Center, Houston, TX,
6. Massachusetts General Hospital, Boston,
7. Chugai Pharmaceutical Co., Ltd., Tokyo, Japan,
8. Debiopharm International SA, Lausanne, Switzerland